Remove Documentation Remove Drug Pricing Remove Pharmaceutical Manufacturing
article thumbnail

DSCSA Compliance: The Time is Now

Pharmaceutical Commerce

27 of this year to meet the requirements, as long as they are making documented efforts to finalize data connections, of course. In fact, wholesalers and repackagers had until May 27, 2025 (following this day, full-unit traceability would be mandatory), a date that has officially passed.

article thumbnail

Navigating 340B Program Changes in 2025

Proxsys Rx

billion annually because of these restrictions, as drug companies limit 340B discounts on medications purchased through contract pharmacies. billion in 340B savings is at risk, due to increasing limitations imposed by pharmaceutical manufacturers which could further strain the healthcare safety net and patient care services.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NOW AVAILABLE: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

drug pricing, reimbursement, and dispensing system. There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities. The 2022 Economic Report on U.S. The report has been thoroughly updated with the latest data and includes loads of new material and new sections.

article thumbnail

What is HEOR in Pharma?

Viseven

The list of HEOR competencies includes, but is not limited to, clinical trial design, epidemiology, HEOR modeling, statistics, data mining, collecting and processing statistics and documenting real-world evidence. How Pharmaceutical HEOR Experts impact Drugs Engineering. HEOR Impact on Drug Pricing and Marketing.

article thumbnail

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

BioPharma Dive

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

article thumbnail

What Does the “Most Favored Nation” Executive Order Mean for Personal Use Imports?

FDA Law Blog: Biosimilars

Wasserstein We are still parsing through the May 12 Executive Order (EO), Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients and impacts this may have on the pharmaceutical industry. Final Rule, Importation of Prescription Drugs , 85 Fed. Please bear with us.) 62,094, 62,097 (Oct.